問卷

TPIDB > Principal Investigator

Principal Investigator


Koo Foundation Sun Yat-Sen Cancer Center (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

鍾奇峰
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

90Cases

2017-03-01 - 2019-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2015-12-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2016-12-15 - 2020-06-08

Phase III

Not yet recruiting
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Asian Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine
  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Keytruda

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2020-08-31 - 2026-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2022-03-01 - 2027-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2022-04-01 - 2027-03-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2014-10-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2025-02-28 - 2032-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2023-10-16 - 2026-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-06-01 - 2026-12-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites